The magnitude and durability of immune response to the SARS-CoV-2 vaccination among children
Ausmaß und Dauer der Immunantwort auf die SARS-CoV-2-Impfung bei Kindern
Journal of the Pediatric Infectious Diseases Society · 06.11.2026
DOI: 10.1093/jpids/piag117 ↗Auf einen Blick
Bei Kindern nahmen die humoralen SARS-CoV-2-spezifischen Antworten bis 6 Monate nach der zweiten Dosis ab. T-Zell-Antworten zeigten über 12 Monate wenig Abnahme.
Fragestellung
Wie stark und wie dauerhaft sind SARS-CoV-2-spezifische Immunantworten bei Kindern nach der Impfung, und wie unterscheiden sie sich zwischen Ungeimpften sowie Kindern mit 2 oder 3 Dosen?
Methode
Drei longitudinale Beobachtungskohorten mit Kindern 3–14 Jahre in Montreal, Kanada, von Dezember 2021 bis Oktober 2023; Serologie vor der 2. Dosis sowie 1, 6 und 12 Monate danach bzw. alle 2–3 Monate. Lineare Mixed-Models mit Anpassung für Infektionsanamnese.
Ergebnisse
Anti-spike IgG, Anti-RBD-IgG und neutralisierende Titer gegen Wildtyp-SARS-CoV-2 sanken bis 6 Monate nach Impfung. Anti-RBD-IgG: 1 374,1 BAU/mL nach 1 Monat, Abnahme um −856,1 BAU/mL nach 6 Monaten (95 %-KI −1 303,5 bis −596,0; p<0,0001).
Schlussfolgerung der Autor:innen
Humorale Antworten nahmen innerhalb von 6 Monaten nach der Impfung deutlich ab. Zelluläre Antworten waren zwischen den Impfstatus-Gruppen vergleichbar; geimpfte Kinder behielten über mehr als 1 Jahr tendenziell höhere Werte.
Kernaussagen
- Humorale Marker nahmen bis 6 Monate nach der 2. Dosis ab.
- Anti-RBD-IgG: −856,1 BAU/mL nach 6 Monaten (95 %-KI −1 303,5 bis −596,0)
- T-Zell-Antworten zeigten wenig Abnahme über 12 Monate.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, online erschienen am 06.11.2026. Verfasst von Katia Charland und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Public Health Research, University of Montreal, Montreal, Quebec, Canada. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The declining uptake of SARS-CoV-2 vaccines, combined with evolving schedules and recurrent infections, underscores the need to monitor the durability of hybrid immunity in children. The objective of this study was to assess children’s SARS-CoV-2-specific immune responses post-second vaccine dose and to compare immune responses between unvaccinated children and children vaccinated with two or three vaccine doses.
Methods
Three observational cohorts of children aged 3–14 years were followed longitudinally from December 2021 to October 2023 in Montreal, Canada. Two had scheduled serology assessments before their second dose and at one, six and twelve months post-second dose. The other cohort included unvaccinated and vaccinated children, with 2-4 serology assessments, every 2-3 months. Linear mixed models adjusting for infection history were used to assess immune waning post-second dose and differences over time by vaccine status.
Results
Controlling for recent infection, anti-spike IgG, anti-receptor binding domain (RBD) IgG, and neutralizing titers against wild-type SARS-CoV-2 declined by six months post-vaccination. For example, average IgG anti-RBD was 1 374.1 BAU/mL one month after dose two, with an estimated decline of −856.1 BAU/mL at six months (95% CI, −1 303.5 to −596.0; p<0.0001). T cell responses showed little evidence of decline over 12 months across all groups with a history of infection. Comparing children by vaccine status, the highest humoral responses were associated with three doses whereas the lowest with unvaccinated status (e.g., crude average two-dose IgG anti-RBD: 920.0 BAU/ml; unvaccinated estimated difference −515.1 BAU/mL; 95% CI, −698.0 to −444.7; p<0.0001). Spike-specific CD4+ T cell responses were lower among the unvaccinated.
Conclusions
Humoral responses declined significantly within six months of vaccination. Cellular responses were comparable across vaccine status groups, yet vaccinated children tended to maintain higher levels for more than one-year post-vaccination. Hybrid immunity could contribute to a more robust and durable cellular response.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Public Health Research, University of Montreal, Montreal, Quebec, Canada.
- Sainte-Justine University Hospital and Research Center, Montreal, Quebec, Canada.
- Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
- McGill University, Montreal, Quebec, Canada.
- Department of Pediatrics, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
- Lunenfeld-Tunenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
ORCID-Profile: Margot Barbosa Da Torre, Manish Sadarangani, Kate Zinszer
Zitieren
APA
Charland, K., Da Torre, M. B., Joly, J. A., Sutton, G., Nantel, S., Bourdin, B., Benea, C., Desjardins, M., Mazer, B., Colwill, K., Qi, F., Gingras, A. C., Sadarangani, M., Quach, C., Decaluwe, H., & Zinszer, K. (2026). The magnitude and durability of immune response to the SARS-CoV-2 vaccination among children. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piag117
Vancouver
Charland K, Da Torre MB, Joly JA, Sutton G, Nantel S, Bourdin B, et al. The magnitude and durability of immune response to the SARS-CoV-2 vaccination among children. Journal of the Pediatric Infectious Diseases Society. 2026. doi:10.1093/jpids/piag117
BibTeX
@article{Charland2026,
author = {Charland, Katia and Da Torre, Margot Barbosa and Joly, Josée-Anne and Sutton, Gabrielle and Nantel, Sabryna and Bourdin, Benoite and Benea, Carla and Desjardins, Mélanie and Mazer, Bruce and Colwill, Karen and Qi, Freda and Gingras, Anne-Claude and Sadarangani, Manish and Quach, Caroline and Decaluwe, Hélène and Zinszer, Kate},
title = {The magnitude and durability of immune response to the SARS-CoV-2 vaccination among children},
journal = {Journal of the Pediatric Infectious Diseases Society},
year = {2026},
doi = {10.1093/jpids/piag117}
}
EUVIMED